Combination of an inhibitor of t790m efgr and a CDK inhibitor for the treatment of non small cell lung cancer

摘要

Claim 1: a method to treat non small cell lung cancer comprising administering to a patient in need thereof a quantity of N - ((3R,4R) - 4 - fluoro - 1 - (6 - ((1 - methyl - 3 - methoxy - 1h-pyrazol-4-yl) amino) - 6 - methyl - 2 - 9h purin - il) pyrrolidin-3-yl) acrylamide, or a pharmaceutically acceptable Salt thereof, and a quantity of palbociclib,Or a pharmaceutically acceptable Salt thereof, where the quantities together are effective in the treatment of non-small cell lung cancer.A synergistic combination of claim 14: (a) n - ((3R, 4R) - 4 - fluoro - 1 - (6 - ((1 - methyl - 3 - methoxy - 1h-pyrazol-4-yl) amino) - 6 - methyl - 2 - 9h purin - yl) - pyrrolidin-3-yl 3 - il) acrylamideOr a pharmaceutically acceptable Salt thereof; and (b) palbociclib or a pharmaceutically acceptable Salt thereof; wherein the component (a) and component (b) are Synergistic.